机构:[1]Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310029, China 浙江大学医学院附属第一医院[2]Institute of Fundamental and Transdisciplinary Research, Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310029, China [3]Department of Health Management Center & Institute of Health Management, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan 611731, China 四川省人民医院[4]Cancer Center, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China [5]Department of Clinical Laboratory, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China 浙江省肿瘤医院[6]College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, Zhejiang 310018, China [7]Department of Oncology, the Affiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao, Shandong 266071, China [8]Zhejiang Key Laboratory of Multi-omics Precision Diagnosis and Treatment of Liver Diseases, Department of General Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, China [9]State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
This study was supported by grants from the National Natural Science
Foundation of China (82188102 and 82030074, Z. Lu; 82372816, D.G.;
81872239 and 82273088, Q. Yu; 82203576, Y.T.; 82272406, X.Q.; and
82203553, Y.M.), the Ministry of Science and Technology of the People’s
Republic of China (2020YFA0803300, Z. Lu), the National Center of Technology Innovation for Biopharmaceuticals (NCTIB2022HS02006, Z. Lu),
and Hangzhou Institute of Medicine Chinese Academy of Sciences
(2024ZZBS12, X.Q.). Z. Lu is the Kuancheng Wang Distinguished Chair.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
无
最新[2023]版:
大类|1 区生物学
小类|1 区生化与分子生物学1 区细胞生物学
第一作者:
第一作者机构:[1]Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310029, China [2]Institute of Fundamental and Transdisciplinary Research, Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310029, China
共同第一作者:
通讯作者:
通讯机构:[1]Zhejiang Provincial Key Laboratory of Pancreatic Disease, the First Affiliated Hospital, Zhejiang Key Laboratory of Frontier Medical Research on Cancer Metabolism, Institute of Translational Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310029, China [2]Institute of Fundamental and Transdisciplinary Research, Cancer Center, Zhejiang University, Hangzhou, Zhejiang 310029, China
推荐引用方式(GB/T 7714):
Guo Dong,Yu Qiujing,Tong Yingying,et al.OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth[J].Molecular Cell.2025,doi:10.1016/j.molcel.2024.12.025.
APA:
Guo Dong,Yu Qiujing,Tong Yingying,Qian Xu,Meng Ying...&Lu Zhimin.(2025).OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth.Molecular Cell,,
MLA:
Guo Dong,et al."OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth".Molecular Cell .(2025)